Sanofi (India) announced that it has received marketing authorization for its diabetes drug Soliqua (in pre-filled pen) from the Central Drugs Standard Control Organization (CDSCO).
Soliqua is indicated as treatment to improve glycaemic control as an adjunct to diet and exercise, in adults with obesity and type 2 diabetes who are insufficiently controlled on oral or injectable therapies. It comes in once daily dosing of pre-filled pens in fixed-ratio combination (10-40 and 30-60) of insulin glargine and lixisenatide.
Cyrus Aibara, head
